Advanced Search
Therapeutic Area Disease
Title Drug Phase
Clinical Trials Listing
Active treatment trials at Penn's Abramson Cancer Center
Protocol ID Title Phase Modality Drug
UPCC 16412 A Phase 3, Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physician's Choice of Treatment Administered to Patients With Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis III Chemotherapy, Hormonal Therapy, Immunotherapy, Signal Transduction Inhibitor melphalan; thalidomide; cyclophosphamide; dexamethasone; lenalidomide; ixazomib
710 Allogeneic Hematopoietic Cell Transplant for Hematological Cancers and Myelodysplastic Syndromes in HIV-Infected Individuals II Chemotherapy, Radiotherapy fludarabine; busulfan; melphalan; cyclophosphamide
UPCC-15411 A Phase I-II Open Label Non-Randomized Study Using TL32711 for Patients With Acute Myelogenous Leukemia, Myelodysplastic Syndrome and Acute Lymphoblastic Leukemia I / II Biological Therapy birinapant
UPCC 12413 A Phase 1b/2a, Open-label, Non-randomized Study of Birinapant in Combination With 5-azacitidine in Subjects With Myelodysplastic Syndrome Who Are Refractory or Have Relapsed to 5-azacitidine Therapy I / II Biological Therapy, Chemotherapy azacitidine; birinapant
UPCC-42413 A Phase 1 Study of CPI-0610, a Small Molecule Inhibitor of BET (Bromodomain and Extra-terminal) Proteins, in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelodysplastic/Myeloproliferative Neoplasms I Signal Transduction Inhibitor CPI-0610
BMTCTN1102 A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 w/Intermediate-2 & High Risk Myelodysplastic Syndrome Blood and Marrow Transplant Clinical Trials Network #1102) Not Specified Biological Therapy Not Applicable
Active non-treatment trials at Penn's Abramson Cancer Center
Protocol ID Title Phase Modality Drug
AT005074 Long-Term Chamomile Therapy for Generalized Anxiety Disorder (GAD) III Supportive Care Not Applicable
NCI-2009-01173 Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment With Lenalidomide (Revlimid[R]) Alone and in Combination With Epoetin Alfa (Procrit[R]) in Subjects With Low- or Intermediate-1 Risk MDS and Symptomatic Anemia III Immunotherapy, Signal Transduction Inhibitor lenalidomide; epoetin alfa
AZA-MDS-003 A Phase 3, Multicenter, Randomized, Double-blind Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Subjects With Red Blood Cell Transfusion-dependent Anemia and Thrombocytopenia Due to IPSS Lower-risk Myelodysplastic Syndromes III Chemotherapy azacitidine
UPCC-05912 Extended Duration Varenicline for Smoking Among Cancer Patients: A Clinical Trial III Other, Supportive Care varenicline tartrate
UPCC-04712 A Phase II Study to Assess the Efficacy of Maraviroc, a CCR5-Antagonist in Prophylaxis of Graft-Versus-Host Disease in Patients With Hematologic Malignancies Undergoing Reduced-Intensity Allogeneic Stem-Cell Transplantation From Unrelated Donors II Antiviral Therapy Maraviroc
UPCC 01914 Patient-Centered Integration of Acupuncture to Decrease Pain for Cancer Survivors Not Specified Pain Management Not Applicable
UPCC-12807 Assessing Fertility Potential in Female Cancer Survivors Not Specified Imaging Procedure, Blood Test Not Applicable
Active advanced solid tumor trials at Penn's Abramson Cancer Center
Protocol ID Title Phase Modality Drug

Sorry, your search did not return any Phase 1: Solid Tumor Trials trials

Active proton therapy trials at Penn's Abramson Cancer Center
Protocol ID Title Phase Modality Drug

Sorry, your search did not return any Proton Therapy Trials trials